Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Craig Tooman
|
| gptkbp:collaboratesWith |
gptkb:Mallinckrodt_Pharmaceuticals
gptkb:AstraZeneca |
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:focusesOn |
RNA interference therapeutics
|
| gptkbp:founded |
1994
|
| gptkbp:headquartersLocation |
gptkb:London
|
| https://www.w3.org/2000/01/rdf-schema#label |
Silence Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:London_Stock_Exchange
|
| gptkbp:officeLocation |
gptkb:Berlin
gptkb:New_Jersey |
| gptkbp:platform |
siRNA (small interfering RNA)
|
| gptkbp:products |
SLN124
SLN360 |
| gptkbp:researchInterest |
cardiovascular diseases
rare diseases |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:SLN
|
| gptkbp:subsidiary |
Silence Therapeutics GmbH
|
| gptkbp:tradedOn |
gptkb:SLN
|
| gptkbp:website |
https://www.silence-therapeutics.com/
|
| gptkbp:bfsParent |
gptkb:RTW_Investments
|
| gptkbp:bfsLayer |
8
|